Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
12.48
-1.00 (-7.42%)
Mar 12, 2026, 4:00 PM EDT - Market closed
Arvinas Employees
Arvinas had 246 employees as of December 31, 2025. The number of employees decreased by 184 or -42.79% compared to the previous year.
Employees
246
Change (1Y)
-184
Growth (1Y)
-42.79%
Revenue / Employee
$1,067,480
Profits / Employee
-$328,455
Market Cap
798.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 246 | -184 | -42.79% |
| Dec 31, 2024 | 430 | -15 | -3.37% |
| Dec 31, 2023 | 445 | 30 | 7.23% |
| Dec 31, 2022 | 415 | 135 | 48.21% |
| Dec 31, 2021 | 280 | 101 | 56.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Phathom Pharmaceuticals | 371 |
| Kura Oncology | 260 |
| Omeros | 202 |
| ARS Pharmaceuticals | 163 |
| Sana Biotechnology | 142 |
| CytomX Therapeutics | 121 |
| Ocugen | 116 |
| Annexon | 99 |
ARVN News
- 1 day ago - Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders - GlobeNewsWire
- 2 days ago - Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 17 days ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewsWire
- 4 weeks ago - Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director - GlobeNewsWire
- 3 months ago - Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire